Table 2.
ID | Tumour Type | Cohort | Tumour Cell Content (%) | Rearrangement | # READS | Reading Frame |
---|---|---|---|---|---|---|
4_DRIVER FREE | MEL | Driver Free | 90 | BRAF Domain Duplication | 258 | In frame |
53_DRIVER FREE | MEL | Driver Free | 80 | EGFR ex26→LOC100996654 | 45/67 | n.a. |
34_MSI | CRC | MSI-CRC | 60 | TPM3 ex7→NTRK1 ex10 | 72/513 | In frame |
11_DRIVER FREE | LAC | Driver Free | 70 | ETV6 ex4→NTRK3 ex14 | 23/23 | In frame |
1_MSI | CRC | MSI-CRC | 50 | ETV6 ex5→NTRK3 ex15 | 33/45 | In frame |
3_MSI | CRC | MSI-CRC | 80 | HGF intron16→ALK ex2 | 10/21 | Out of frame |
48_DRIVER FREE | MEL | Driver Free | 80 | MET ex14 skipping | 342 | In frame |
28_MSI | CRC | MSI-CRC | 50 | STRN ex3→ALK ex20 | 78/252 | In frame |
53_MSI | CRC | MSI-CRC | 70 | TRIM24 ex3→BRAF ex10 | 61/170 | In frame |
55_MSI | CRC | MSI-CRC | 80 | CCDC6 ex1→RET ex12 | 122/784 | In frame |
44_MSI | CRC | MSI-CRC | 70 | NCOA4 ex9→RET ex12 | 54/68 | In frame |
MSI—microsatellite instability; CRC—colorectal cancer; LAC—lung adenocarcinoma; MEL—melanoma; n.a.—not assessable.